Reduced nuclear NAD+ drives DNA damage and subsequent immune activation in the retina

Emily E. Brown(Massachusetts Eye and Ear Infirmary), Eric A. Pierce(Broad Institute), Jianhai Du(West Virginia University), Michael J. Scandura(Massachusetts Eye and Ear Infirmary), Sudeep Mehrotra(Massachusetts Eye and Ear Infirmary), Yekai Wang(West Virginia University)
Human Molecular Genetics
November 5, 2021
10.1093/hmg/ddab324
Cited by 15

Related Papers

Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.
|Proceedings of the National Academy of Sciences|1995|1k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration
|Molecular Therapy|2009|551